MICAL1 Monooxygenase in Autosomal Dominant Lateral Temporal Epilepsy: Role in Cytoskeletal Regulation and Relation to Cancer

Genes (Basel). 2022 Apr 19;13(5):715. doi: 10.3390/genes13050715.

Abstract

Autosomal dominant lateral temporal epilepsy (ADLTE) is a genetic focal epilepsy associated with mutations in the LGI1, RELN, and MICAL1 genes. A previous study linking ADLTE with two MICAL1 mutations that resulted in the substitution of a highly conserved glycine residue for serine (G150S) or a frameshift mutation that swapped the last three C-terminal amino acids for 59 extra residues (A1065fs) concluded that the mutations increased enzymatic activity and promoted cell contraction. The roles of the Molecule Interacting with CasL 1 (MICAL1) protein in tightly regulated semaphorin signaling pathways suggest that activating MICAL1 mutations could result in defects in axonal guidance during neuronal development. Further studies would help to illuminate the causal relationships of these point mutations with ADLTE. In this review, we discuss the proposed pathogenesis caused by mutations in these three genes, with a particular emphasis on the G150S point mutation discovered in MICAL1. We also consider whether these types of activating MICAL1 mutations could be linked to cancer.

Keywords: LGI1; MICAL1; RELN; autosomal-dominant lateral temporal epilepsy; axonal development; cancer genomics; semaphorin signaling.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Epilepsy, Temporal Lobe* / genetics
  • Epilepsy, Temporal Lobe* / pathology
  • Humans
  • Microfilament Proteins / genetics
  • Mixed Function Oxygenases / genetics
  • Mutation
  • Neoplasms*
  • Proteins / genetics

Substances

  • MICAL1 protein, human
  • Microfilament Proteins
  • Mixed Function Oxygenases
  • Proteins

Grants and funding